Trials in castration-resistant prostate cancer (CRPC) need new clinical end points that are valid surrogates for survival. We evaluated circulating tumor cell (CTC) enumeration as a surrogate outcome measure.
INTRODUCTION
The recent progress in prostate cancer therapeutics is unprecedented. In a 3-year period, five different therapies were proven to prolong life in patients with progressive castration-resistant disease (CRPC). [1] [2] [3] [4] [5] [6] [7] The results give new hope to those in need of effective treatment, but at the same time, the availability of more life-prolonging treatments makes it more difficult to demonstrate a survival benefit for future new drugs. Future trials designed with a primary end point of survival will have to be larger, longer running, and more costly, with a higher risk of failure. Urgently needed are reproducible and reliable posttreatment outcome measures that are surrogates for survival that can be used to guide patient management and facilitate regulatory approval. Such surrogates would make new drugs available to patients more rapidly and significantly reduce drug development timelines and costs.
Shedding of tumor cells into the circulation is a necessary (but not sufficient) step for the formation of metastases, 8 and multiple assays and devices are now available to detect, isolate, enumerate, and characterize circulating tumor cells (CTCs), 9 but only one, CellSearch (Janssen Diagnostics, Raritan, NJ), is US Food and Drug Administration cleared 10, 11 "as an aid in the monitoring of patients" based on trials in metastatic breast cancer, metastatic colorectal cancer, and metastatic CRPC (mCRPC) . Trials demonstrated that the number of CTCs measured during the course of treatment, reported as unfavorable (Ն 5 cells/7.5 mL of blood) versus favorable (Յ 4 cells/7.5 mL), is prognostic and predictive of overall survival. [12] [13] [14] One mechanism contributing to CRPC progression is upregulation of the androgen biosynthetic machinery that leads to an increase in intratumoral androgens. 15, 16 Abiraterone acetate is a prodrug of abiraterone, which is a selective CYP450 17A1 inhibitor that reduces androgen production in the testes, adrenal glands, and tumor tissues 17 and lowers serum testosterone levels to the 1-ng/dL range. 18 A concern in the development of this and other androgen-modulating agents has been that post-therapy prostate-specific antigen (PSA) declines may 0 to 3  426  54  219  56  278  57  134  59  4 to 10  359  46  170  44  206  43  93  41  No. of prior chemotherapy regimens  1  557  70  275  69  356  74  161  71  2  240  30  123  31  128  26  66  29  Type of disease progression at baseline  PSA only  238  30  125  31  145  30  78  34  Radiographic Ϯ PSA  559  70  273  69  339  70  149  66  Extent of disease at baseline  n ϭ 225  Bone  710  89  358  91  429  89  197  88  Nodal  361  45  164  42  231  48  87  39  Visceral (liver and/or lung)  173  22  65  16  88  18  28 12 Baseline CTC count, cells/7.5 mL † n ϭ 595 n ϭ 300 n ϭ 457 n ϭ 217 0 to 4  292  49  134  45  243  53  110  51  Ն 5  303  51  166  55  214  47  107  49  Median  5  6  4 4 Range 0 to 100.1 0 to 100.1 0 to 100.1 0 to 100.1 Baseline LDH, U/L n ϭ 783 n ϭ 386 n ϭ 480 n ϭ 222 Ͼ 250  302  39  168  44  144  30  72  32  Յ 250  481  61  218  55  336  70  150  68  Median  223  238  211  222  Range  84 to 3,373  123 not reflect a favorable effect on tumor growth. [19] [20] [21] [22] To address this, CTC enumeration using CellSearch was explored as a secondary end point in two phase II trials of abiraterone acetate in patients with mCRPC experiencing progression after chemotherapy. Both trials showed significant and durable declines in PSA and favorable changes in CTC count. 23, 24 A separate analysis showed that each of the following was strongly prognostic for survival pre-and post-treatment: a biomarker panel containing CTC count alone, a panel containing lactate dehydrogenase (LDH) alone, and a panel containing the combination of CTC count and LDH level. All were stronger than PSA.
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On the basis of those results, CTC enumeration was included as an outcome measure in the abiraterone acetate phase III registration trial (COU-AA-301) in patients with mCRPC previously treated with docetaxel; the primary end point was overall survival. The aim was to identify a biomarker or biomarker panel using the Prentice 25 criteria that could serve as an efficacy-response surrogate for overall survival, to be confirmed in future trials. The biomarker aspects of the trial design were reviewed by the US Food and Drug Administration Centers for Devices and Radiological Health and Drug Evaluation Research.
PATIENTS AND METHODS

Study Design and Patients
The trial was conducted at 147 sites in 13 countries in North America, Europe, and Australia. CTC samples were not collected in Australia for logistic reasons. Details of the methodology, patient population, and treatment have been reported previously, along with interim and final study results.
2, 3 Patients were stratified by the four baseline factors listed in Table 1 (ie, Eastern Cooperative Oncology Group status, worst pain level, number of prior chemotherapy regimens, and type of disease progression) and then randomly assigned at a ratio of 2:1 to receive abiraterone acetate 1,000 mg daily or matched placebo; both groups received prednisone 10 mg daily. Treatment was continued until disease progression based on PSA determinations, imaging, and/or clinical criteria or until unacceptable toxicity. The review boards at all participating institutions approved the study, which was conducted according to the principles set forth in the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonisation. All patients provided written informed consent to participate. CTC numbers were measured using CellSearch. One of the secondary objectives was to explore CTC number as a potential surrogate for survival.
Biomarker Panel
Factors measured at monthly intervals post-treatment were considered, with the addition of PSA, which was measured only every 12 weeks to maintain study blinding. The factors were CTC, PSA, LDH, hemoglobin, albumin, and alkaline phosphatase levels, based on inclusion in published nomograms for this population. 26, 27 Cut points for each variable were based on the upper or lower limits of normal: LDH, 250 U/L; hemoglobin, 12 g/dL; albumin, 4 g/dL; and alkaline phosphatase, 130 U/L. For CTC number, the US Food and Drug Administrationapproved cutoff values for favorable (Յ 4 cells/7.5 mL) and unfavorable counts (Ն 5 cells/7.5 mL) were used, and for PSA, 30% and 50% decreases from baseline to week 12 were used, respectively. Each biomarker panel tested included CTCs, in accordance with the secondary objective of the trial, analyzed in one of three ways: fixedtimepoint(eg,absoluteCTCcountat12weeks),differencefrombaseline(eg, CTC count at 12 weeks minus baseline CTC count), or relative difference from baseline (eg, percent change in CTC count from baseline to 12 weeks).
Surrogacy Analyses
The Prentice 25 criteria were applied to assess the surrogate at the individual-patient level (Table 2 ). Prentice criterion one was assessed using a stratified log-rank test, criterion two using the score test from the proportional odds model, and criterion three using the likelihood ratio test from the stratified Cox model. The inverse-probability weighted c-index was used to scan for possible CTC-based surrogate biomarker combinations and to provide a quantitative measure of Prentice criterion three. 28 The test to determine if Prentice criterion four was satisfied is described in the Data Supplement. The test is based on the proportional hazards model, and a test of proportionality based on the Schoenfeld residuals was applied.
29 If the proportional hazards assumption was rejected, a non-model-based approach was used to evaluate Prentice criterion four. For more details on testing the proportional hazards assumption, see the Data Supplement.
To test the sensitivity of the surrogacy analysis to the exclusion of patients with missing 12-week biomarker data, surrogacy was reassessed by imputing the latest postbaseline biomarker data recorded Յ 12 weeks from the start of treatment as the surrogate value for each patient. Thus, if a patient had marker values at weeks 4 and 8, but was missing a week-12 value for a marker, we used the week-8 value as the surrogate.
RESULTS
In this phase III trial, 1,542 patients were assessed for eligibility, 1,195 were enrolled, 1,091 survived for at least 12 weeks, and 899 had postbaseline CTC and LDH data and were observed for at least 12 weeks. Of the 296 patients who did not have CTC or LDH data recorded at week 12, 86 died or were withdrawn from the study before week 12. Thirty-four of the 86 patients were randomly assigned to receive prednisone alone, and 52 were randomly assigned to receive abiraterone acetate plus prednisone. The finalanalysisincludedatotalof711patientswithbothCTCandLDHdata recorded at week 12 (Fig 1) . The baseline demographics and 12-week marker values for these patients are listed in Tables 1 and 3 , respectively. The Kaplan-Meier estimates of overall survival by treatment group (Data Supplement) showed a statistically significant (P ϭ .035) and clinically meaningful survival difference between the abiraterone acetate plus prednisone and prednisone-alone groups (17.7 v 15.1 months; hazard ratio, 0.80; 95% CI, 0.65 to 0.98), which mirrored the previously reported survival benefit shown in the overall intent-to-treat population.
2,3 This finding satisfied Prentice 25 criterion one and provided the framework for evaluating a surrogate end point for survival.
A landmark analysis at 12 weeks was used to explore the discriminatory power of CTC count alone or CTC-containing biomarker combinations. For a two-biomarker combination, the categorization of risk groups was 0, 1, or 2, representing the number of markers above the upper limit or below the lower limit of normal, as appropriate. The results listed in Table 4 indicate that CTC count alone provided the strongest discrimination between risk groups, followed by CTC count in combination with LDH level and LDH level alone. However, for the CTC count-alone and LDH level-alone biomarkers, the proportional hazards assumption was not satisfied (global test of proportionality ‫ء‬ CTC count Ͼ 100 cells/7.5 mL was entered as 100.1 in database. Australian patients did not contribute CTC enumeration data. Abbreviations: ALB, albumin; ALK, alkaline phosphatase; CTC, circulating tumor cell; HGB, hemoglobin; LDH, lactate dehydrogenase; PSA, prostatespecific antigen; PSA 30 , 30% decrease in PSA from baseline to week 12; PSA 50 , 50% decrease in PSA from baseline to week 12. ‫ء‬ For two-biomarker combination, categorization of risk groups was 0, 1, and 2, which represented number of markers above or below the upper or lower limit of normal.
†Weighted c-index evaluated concordance between risk group score at 12 weeks and survival time.
‡P value was based on bootstrap test comparing weighted c-indices of biomarker combinations with CTC plus LDH biomarker combination; significant P value (Ͻ .05) was indication that CTC plus LDH combination had higher c-index. §Most panels were tested using only absolute values (first option listed under Patients and Methods, Biomarker Panel). Exceptions were CTC absolute change (second option), CTC relative change (third option), and CTC plus PSA 50 (PSA 50 was dichotomous variable based on relative difference from baseline). Absolute change of CTC biomarker from baseline to week 12; threshold chosen for absolute change was 0.50, derived from regression tree analysis.
¶Relative change of CTC biomarker from baseline to week 12; threshold chosen for relative change was 0.15, derived from regression tree analysis. P ϭ .04), and Prentice 25 criterion four was not attained using a nonmodel-based evaluation (Data Supplement). As a result, we proceeded to construct a biomarker panel with the CTC plus LDH combination biomarker. For completeness, Table 4 summarizes the discriminatory power of all single-and two-factor combinations. The P values were based on a bootstrap test comparing the weighted c-indices of each biomarker combination with the CTC plus LDH combination. As shown, non-CTC-based combinations had significantly smaller c-indices than the CTC plus LDH combination.
The four Prentice 25 criteria were satisfied using a constructed CTC plus LDH biomarker, categorized as: low (CTCs Յ 4; any LDH), intermediate (CTCs With the three risk groups defined by the CTC plus LDH biomarker, the prednisone-alone group had a higher percentage of highrisk, poor-prognosis patients and a lower percentage of low-risk, better-prognosis patients than the abiraterone acetate plus prednisone group (Table 5) at 12 weeks. The treatment effect on the surrogate, using a stratified score statistic from the proportional odds regression model, was statistically significant (P Ͻ .001), indicating that the surrogate distribution differed by treatment, satisfying Prentice 25 criterion two. Figure 2A shows the Kaplan-Meier estimates of survival for the three surrogate risk categories based on the 12-week CTC and LDH values. Median overall survival for the high-, intermediate-, and lowrisk groups was, respectively: 8.71 (95% CI, 7.8 to 9.63), 12.02 (95% CI, 1.68 to 15.31), and 22.18 months (95% CI, 2.83 to upper limit not reached). The three surrogate groups separated patient risk, and the result of the stratified log-rank test for the surrogate effect on survival was statistically significant (P Ͻ .001). The weighted c-index for the three surrogate risk categories was 0.81 (SE, 0.02), a high value that provides strong evidence that the surrogate was able to discriminate survival time, satisfying Prentice 25 criterion three. Table 5 lists the 1-and 2-year survival probabilities, respectively, by risk group: 82% and 46% (low-), 51% and 10% (intermediate-), and 25% and 2% (highrisk patients).
Prentice 25 criterion four requires that treatment assignment is independent of survival once the surrogate is accounted for. This was carried out as a test of equivalence between the Cox survival model based on treatment assignment and the surrogate, and the model based on the surrogate alone. The proportionality assumption for these models could not be rejected (global tests of proportionality, P ϭ .13 and P ϭ .33). Details are supplied in the Data Supplement. The P values for this test of equivalence were calculated for each month between 6 and 24 months and adjusted to account for multiple testing. The maximum adjusted P value was less than .001. This significant result showed equivalence; the Cox survival model derived with the surrogate and the treatment assignment was equivalent to the survival model based on the surrogate alone at each monthly time point between 6 and 24 months. This indicated that there was little added value to including treatment assignment in the model and that Prentice criterion four was satisfied. A depiction of the lack of treatment effect after accounting for the surrogate is provided in Figure 2B .
The sensitivity analysis, which replaced missing CTC and LDH week-12 data with earlier recorded postbaseline values from 899 patients, supported up to month 20 the attainment of the fourth Prentice criterion. The results are provided in the Data Supplement.
DISCUSSION
Prentice
25 defined a surrogate as a post-treatment measure that both was prognostic for a clinical end point and captured the effect of the treatment on that end point. Establishing a surrogate for survival has the potential to shorten drug development timelines and to minimize the chance of postprotocol therapy masking the survival benefit of an experimental drug. Data from multiple trials across a range of cancers have shown that patients with detectable CTCs in blood at the start of a treatment or after treatment have inferior survival times relative to those who do not. Here we show for the first time to our knowledge that a biomarker panel containing CTC number and LDH level satisfied the Prentice criteria for individual-patient surrogacy within a randomized clinical trial where abiraterone acetate plus prednisone improved survival relative to prednisone alone (hazard ratio, 0.74; 95% CI, 0.64 to 0.86; P Ͻ .001). The surrogate categorized patients based on the 12-week levels of CTCs and LDH as low (CTCs Ͻ 5; any LDH), intermediate (CTCs Ն 5; LDH Յ 250), and high risk (CTCs Ն 5 cells/7.5 mL of blood; LDH Ͼ 250 U/L). Applying the Prentice criteria, we showed: a survival advantage for patients receiving the experimental treatment (P Ͻ .001; criterion one); a more favorable change in risk for patients receiving the experimental treatment (P Ͻ .001; criterion two); that the surrogate had a high discriminatory prognostic power based on a low-to high-risk categorization (weighted c-index, 0.81), with a 1-and 2-year survival of 82% and 46% for those with CTCs Յ 4 at 12 weeks versus 25% and 2% for patients with CTCs Ն 5 cells/7.5 mL of blood and an abnormal LDH at 12 weeks (criterion three); and that the treatment effect on survival was eliminated when the surrogate was added to the model (criterion four). The last criterion-the most difficult to satisfy-was demonstrated using a test of conditional independence, where the survival model based on the treatment and the surrogate was equivalent to the model using the surrogate alone (Fig 2B) . The results were supported by a sensitivity analysis that replaced missing 12-week biomarker data with their nearest postbaseline values.
Consistent with reported results in other series, 20,22,30,31 CTC count alone and LDH level alone both showed high discriminatory power with respect to prognosis. The observation that both elevated CTC count (Ն 5 cells/7.5 mL of blood) alone and elevated LDH value alone at week 12 were associated with inferior survival times supports their use as outcome measures in phase II trials in CRPC.
Neither one alone, however, satisfied the rigorous criteria for surrogacy. That LDH level would add to CTC count is plausible, both scientifically and biologically. Tumors that continue to shed cells into circulation are likely to be more aggressive than those that do not, and although LDH level, an indicator of tumor burden, is only elevated in a small proportion of men with progressive CRPC, the impact on survival is highly negative when it is. Other biomarkers for survival reported in various CRPC nomograms, 32-34 such as PSA, hemoglobin, albumin, and alkaline phosphatase, assessed either alone or in combination, did not add to the discriminatory power of the surrogate.
A common methodologic error in testing Prentice 25 criterion four is to perform a test comparing the survival rates between the two treatments, adjust for the surrogate, and conclude that the criterion is satisfied if the adjusted test is not significant. However, this does not imply that the treatment had no effect on survival after this adjustment. To address this, for validation, we used a test for equivalence between the survival function that included the patient surrogate classification and treatment assignment, and the survival function based solely on the surrogate.
A limitation of our study was that only 59% (711 of 1,195) of the patients enrolled had CTC enumeration performed at week 12. However, this was addressed in part by the sensitivity analyses, which included 75% of enrolled patients and demonstrated that the Prentice 25 criteria were still satisfied in this larger subset. In addition, Prentice criterion four has a causal interpretation only if there are no unmeasured confounders that affect the surrogate and the true end point. This was addressed to the extent possible by adjusting the analysis for the protocol-specified stratification factors (Eastern Cooperative Oncology Group status, bone pain index, prior chemotherapy, and type of prior progression).
Establishing surrogacy requires an analytically valid biomarker and multiple appropriately powered and controlled phase III trials. This trial is the first of a series of phase III studies designed to generate evidence to qualify a survival surrogate that can be used for regulatory submissions. Such a surrogate would shorten drug development times and eliminate the potential confounding effects of postprotocol therapy on survival. Ultimately, the validity of an outcome measure as a surrogate for survival requires assessment at the individual-patient level and trial level. Trial-level surrogacy goes beyond the Prentice 25 criteria, because it requires that a treatment-induced change in the surrogate translate to a predictable treatment-induced change in survival over a whole cohort. This is typically tested using a meta-analysis of several randomized trials, with large numbers of patients, addressing the same question. 35 After the initial trial, a series of trials of similar design would continue with a drug of the same class or a drug that targets the same pathway and then proceed to agents with different mechanisms in the same disease state. As examples, the demonstration of surrogacy in HIV was achieved with five trials enrolling more than 5,000 patients 36 and in colorectal cancer with 18 trials enrolling more than 20,000 patients. 37 We await data from additional trials to test if the CTC plus LDH biomarker panel is valid for trial-level surrogacy and subsequent testing in prospective clinical trials.
In 
